Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,059 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,059 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00763776 | Parenchyma Resection of Cirrhotic Liver by the Clamp Crushing Technique and the…(SECCI) | N/A | terminated | Oct 1, 2008 | Assistance Publique - Hôpitaux de Paris | difficulty for the patient recruiting | Enrollment / accrual |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell… | Phase 2 | terminated | Aug 31, 2007 | University of Chicago | Too slow accrual | Enrollment / accrual |
| NCT01292083 | Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer… | N/A | withdrawn | Feb 9, 2011 | University of Southern California | No accrual last 2 years | Enrollment / accrual |
| NCT00942058 | Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell…(CA9CRM) | — | terminated | Jul 20, 2009 | Centre Hospitalier Universitaire de Saint Etienne | Difficult for recruiting | Enrollment / accrual |
| NCT01501240 | Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules…(PriMPa) | — | withdrawn | Dec 29, 2011 | Jae Ho Byun | not stated | Not stated |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell… | Phase 1 | terminated | Sep 3, 2012 | Seagen Inc. | not stated | Not stated |
| NCT01695057 | Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer | N/A | withdrawn | Sep 27, 2012 | University of Southern California | Lack of funding | Funding |
| NCT01403103 | Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer | Early Phase 1 | withdrawn | Jul 27, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally… | Phase 2 | terminated | Nov 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00596830 | Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced… | Phase 3 | terminated | Jan 17, 2008 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT01096732 | Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative…(HIPPoS) | Phase 2 | terminated | Mar 31, 2010 | Lisa Bax | Slow recruitment | Enrollment / accrual |
| NCT01728480 | Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer… | Phase 1 | withdrawn | Nov 19, 2012 | Roswell Park Cancer Institute | Financial Sponsor requested termination | Funding |
| NCT00095641 | S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent… | Phase 2 | withdrawn | Nov 8, 2004 | SWOG Cancer Research Network | no longer studying this disease site | Other (stated, no rule matched) |
| NCT01063998 | A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell… | — | terminated | Feb 5, 2010 | Jason Hafron | Preliminary data did not show expected outcomes. | Other (stated, no rule matched) |
| NCT01128803 | Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response | Phase 1 / Phase 2 | terminated | May 24, 2010 | Nantes University Hospital | not stated | Not stated |
| NCT01215838 | MRI of the Liver With Eovist | — | terminated | Oct 7, 2010 | University of Washington | Unable to meet enrollment expectations. | Enrollment / accrual |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | May 9, 2005 | Bayer | not stated | Not stated |
| NCT01192763 | RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer | Phase 1 | terminated | Sep 1, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With… | Phase 1 | terminated | Oct 12, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally… | Phase 2 | terminated | Sep 20, 2005 | University of Chicago | Study completed | Other (stated, no rule matched) |
| NCT01618253 | Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma | Phase 1 | withdrawn | Jun 13, 2012 | Medical College of Wisconsin | Closed due to poor accrual. | Enrollment / accrual |
| NCT01210131 | Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung…(HX4 in SCLC) | N/A | withdrawn | Sep 28, 2010 | Maastricht Radiation Oncology | not stated | Not stated |
| NCT00862082 | Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Mar 16, 2009 | Proacta, Incorporated | PR104 plus sorafenib was poorly tolerated in patients with advanced HCC | Other (stated, no rule matched) |
| NCT01830322 | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic… | Phase 2 | withdrawn | Apr 12, 2013 | Cornerstone Pharmaceuticals | not stated | Not stated |
| NCT00673049 | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer(NSCLC) | Phase 3 | terminated | May 7, 2008 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated… | Phase 2 | terminated | Nov 14, 2007 | Accelerated Community Oncology Research Network | The study was closed to enrollment when it became clear that enrollment was too slow to complete… | Enrollment / accrual |
| NCT00003486 | Antineoplaston Therapy in Treating Patients With Colon Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic… | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT01073644 | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent)… | — | terminated | Feb 23, 2010 | Pfizer | The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were no… | Safety / toxicity |
| NCT00098527 | FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00906360 | Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or… | Phase 1 | terminated | May 21, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | Phase 2 | withdrawn | Apr 17, 2013 | Dana-Farber Cancer Institute | Sponsor Aveo has withdrawn support for this trial. | Other (stated, no rule matched) |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00615628 | Inheritance of Osteosarcoma & Paget's Disease Through Chromosome 18: | — | terminated | Feb 14, 2008 | State University of New York - Upstate Medical University | low enrollment low enrollment | Enrollment / accrual |
| NCT00697476 | Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive… | Phase 1 / Phase 2 | terminated | Jun 13, 2008 | Armando Santoro, MD | insufficient enrollment | Enrollment / accrual |
| NCT01219907 | Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in… | Phase 1 | withdrawn | Oct 13, 2010 | University of Washington | not stated | Not stated |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | Phase 2 | withdrawn | Nov 29, 2012 | Eanm Research Ltd | Study was withdrawn due to unanticipated hassle in patient recruitment. | Enrollment / accrual |
| NCT01674374 | Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have… | Phase 2 | withdrawn | Aug 28, 2012 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT00916669 | A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in… | Phase 2 | withdrawn | Jun 9, 2009 | Massachusetts General Hospital | sponsor withdrew funding prior to patient enrollment | Enrollment / accrual |
| NCT01781442 | A Post Marketing Surveillance As Required By Philippine Food And Drug Administration | — | withdrawn | Feb 1, 2013 | Pfizer | not stated | Not stated |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | Phase 2 | terminated | Jun 25, 2007 | M.D. Anderson Cancer Center | Closed early for poor accrual. | Enrollment / accrual |
| NCT01466504 | Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in… | — | terminated | Nov 8, 2011 | Dartmouth-Hitchcock Medical Center | Accrual did not meet expectations. Over nearly 2 years just 4 subjects were treated on study. The… | Enrollment / accrual |
| NCT00828594 | Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With… | Phase 1 | terminated | Jan 26, 2009 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | Phase 2 | withdrawn | Jun 11, 2012 | Andrea Harzstark | not stated | Not stated |
| NCT00405873 | Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular… | Phase 2 | terminated | Nov 30, 2006 | Auron Healthcare GmbH | Lack of efficacy | Efficacy / futility |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases… | Phase 1 | terminated | Jul 13, 2009 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell… | Phase 2 | terminated | Jan 31, 2007 | M.D. Anderson Cancer Center | Slow accrual, study terminated. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 27, 2014source: clinicaltrials